Roy van Voorst

"Michael founded BModesto in 2014; I myself came on board as a shareholder in 2016. The company is engaged in parallel importation of pharmaceuticals from other European countries. Later, we also established two sister companies: BMmedical, for the importation of medical devices, and BMclinical, for supplying companies involved in clinical trials. We also have German and English branches.

The resulting BModesto Group grew rapidly for years. We became a recurring name at the Gazellen Awards of Het Financieele Dagblad, and the associated exposure led to regular approaches by interested investors.

Initially, we kept our distance, but from around 2021, the offers started to take on more serious forms. That was the moment for Michael and me to consider exploring the acquisition options more closely. Ultimately, through our house bank Rabobank, we ended up engaging Rembrandt M&A for this purpose."

Our company continued to experience rapid growth, and Michael and I aimed to maintain our focus on daily operations as much as possible. In this regard, we found a reliable partner in Rembrandt; Menno and his team alleviated a significant amount of our workload. This included drafting the information memorandum, compiling a long and shortlist, and guiding the further sales process and negotiations.

A sale to Private Equity was not our preference; we wanted, with consideration for our employees, to avoid the company being fragmented. After all these years, it has become too much our baby.

Fortunately, Rembrandt introduced us to the perfect partner through their network: Uniphar, a pharmaceutical wholesaler from Ireland. Although we were not familiar with the company ourselves, it quickly became apparent that we shared the same vision for the future and the international expansion of the business. The essence of the BModesto Group's character remained unchanged, which was a decisive factor for us.

Michael and I have grown up with BModesto in day trading, where quick decisions are paramount. However, an acquisition process is precisely a long-term endeavor. This is especially true when engaging with a large, publicly traded company like Uniphar. In such cases, it's beneficial to have an acquisition advisor by your side who maintains composure from the outset and possesses more patience than oneself.

In fact, if, as an entrepreneur, you become too engrossed in such an acquisition process, there's a risk of losing focus, potentially diminishing the value of your company. Hence, it's a compelling reason to seek assistance from a professional partner who can effectively mitigate all the noise.

Michael has remained in position as director, while I myself am still affiliated with the company as a consultant. This arrangement enables us to continue adding value, facilitating the sustainable growth of the company. Overall, we are incredibly pleased with the outcome, both in terms of the acquisition amount and the eventual buyer.

Ready for the future

Honest, thorough and thoughtful. Your future plans deserve the best advice. Our approach follows a tightly guided path, leading to a successful transaction in every respect. Curious about the possibilities? We are here to help via the options below.